1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015

Summary
DelveInsight’s, Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Antibody-Drug Conjugate (ADC). The report provides insights on around 200+ products and 160+ different Companies, which are active in this field. The report also throws the light on 60+ different technologies used by the companies for ADCs development. The main objective of this report is to track competitor’s pipeline molecules, related research activities, technologies, collaborations, funding and licensing activities.. The Antibody-Drug Conjugate (ADC) Report helps to identify emerging players with potentially strong product information and to create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Antibody-Drug Conjugate (ADC)-Pipeline Insights, 2015 Report covers the Antibody-Drug Conjugate (ADC) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also highlights the discontinued and inactive projects in pipeline for Antibody-Drug Conjugate (ADC).

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
- DelveInsight’s report provides an Antibody-Drug Conjugate (ADC) Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the Antibody-Drug Conjugate (ADC) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Antibody-Drug Conjugate (ADC) and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Antibody-Drug Conjugate (ADC)
- Track your competitors and develop strategic initiatives to support your drug development activities
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
- Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table Of Contents

Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015
-Antibody-Drug Conjugate (ADC) Overview
- Antibody-Drug Conjugate (ADC) Pipeline Therapeutics
- Antibody-Drug Conjugate (ADC) Therapeutics under Development by Companies
- Antibody-Drug Conjugate (ADC) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Antibody-Drug Conjugate (ADC) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Antibody-Drug Conjugate (ADC) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Antibody-Drug Conjugate (ADC) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Antibody-Drug Conjugate (ADC)- Discontinued Products
- Antibody-Drug Conjugate (ADC) - Dormant Products
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables
-Number of Products under Development for Antibody-Drug Conjugate (ADC), 2015
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
- Comparative Analysis mid Clinical Stage Products (Phase II), 2015
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
- Drug Candidates Profiles
Antibody-Drug Conjugate (ADC) Therapeutics - Discontinued Products
- Antibody-Drug Conjugate (ADC) Therapeutics - Dormant Products
- Products under Development by Companies, 2015

List of Figures
-Number of Products under Development for Antibody-Drug Conjugate (ADC), 2015
- Late Clinical Stage Products (Filed and Phase III), 2015
- Mid Clinical Stage Products (Phase II), 2015
- Early Clinical Stage Products (Phase I and IND Filed), 2015
- Discovery and Pre-Clinical Stage Products, 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.